Navigation Links
New Pixantrone Data Presented at Meetings at American Society of Hematology Conference
Date:12/6/2010

once the survival and PFS data are mature. The summary update presented at ASH meeting is available for viewing on the Company's website www.celltherapeutics.com.

About the PIX301 EXTEND trial: PIX301 is the largest and only randomized trial comparing single agent pixantrone to a list of physician's choice of standard chemotherapy to patients with relapsed or refractory aggressive NHL who have failed two or more lines of therapy. There are currently no approved or effective agents for these patients. The successful PIX301 study results formed the basis of the Company's recent MAA submission to the EMA which was validated and accepted for review on November 17th, 2010.

In addition on December 2, 2010 the Company filed a formal appeal with the U.S. Food and Drug Administration (the "FDA") under the FDA's dispute resolution proceedings. The basis for the appeal is based on the Company's belief that the FDA diverged from accepted statistical principles and practices when the FDA applied a more stringent statistical significance level in concluding that the PIX301 primary analysis required an adjustment for type 1 error as if an interim analysis had been conducted. This was not the case in the PIX301 trial where only a single final analysis was undertaken. The Company expects to have a response to the appeal in the first quarter of 2011.

About PIX203 trial design: The PIX203 trial is a first-line randomized phase II study of the CHOP-R versus CPOP-R in high risk and elderly patients with previously untreated DLBCL  The study evaluates replacing doxorubicin in the standard CHOP-R combination regimen with pixantrone as part of the CPOP-R regimen. The objective of the study was to demonstrate non-inferior complete response rates to standard doxorubicin-based therapy while producing significantly less severe acute and chronic cardiac toxicities. The Company plans to submit the results of this study for
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. EMEA Validates Cell Therapeutics, Inc.s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
4. Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkins Lymphoma
5. Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
6. Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009
7. Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology
8. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
9. Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... of a field clinical study of its canine osteoarthritis stem cell product, currently ... Therapeutics (Kansas City, KS) and will be marketed in the US by Aratana. ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/29/2015)... 30, 2015 Sanofi, un ... ses résultats pour le premier semestre 2015. Le ... résultats. Visionner l,interview vidéo et lire ... Au sommaire de l,interview :  ... de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Aug. 3, 2011 Neuralstem, Inc. (NYSE Amex: ... of Defense (DOD) contract to develop its human neural ... tumors. The research contract, entitled "Research to Treat Cancerous ... out in collaboration with Principal Investigator John Zhang, MD, ...
... 2011 Cambrex Corporation (NYSE: CBM ) reports second ... Highlights Reported sales increased by ... compared to the second quarter of 2010. EBITDA was $13.2 ... compared to $12.1 million in the second quarter of 2010. ...
... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ... on Monday, August 8, 2011, after the U.S. financial markets ... webcast on Monday, August 8, 2011, at 5:00 p.m. Eastern ... and highlights.  A live webcast of the call will be ...
Cached Biology Technology:Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 2Neuralstem Awarded Department of Defense Contract for Brain Cancer Research 3Cambrex Reports Second Quarter of 2011 Results 2Cambrex Reports Second Quarter of 2011 Results 3Cambrex Reports Second Quarter of 2011 Results 4Cambrex Reports Second Quarter of 2011 Results 5Cambrex Reports Second Quarter of 2011 Results 6Cambrex Reports Second Quarter of 2011 Results 7Cambrex Reports Second Quarter of 2011 Results 8Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2
(Date:7/7/2015)... , June 30, 2015 ... has announced the addition of the "Capacitive ... offering. To this date, fingerprint sensing ... technology and fingerprint sensors are well developed. This ... sensing technology. The domain of capacitive ...
(Date:7/2/2015)... 25, 2015 Research and ... "Next Generation Biometrics Market by Application, Technology, Function ... to their offering. The next generation biometrics ... at a CAGR of 17.9% between 2015 and 2020 ... for the market. Safran SA ( ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2
... and gas concessions threatens the megadiverse Peruvian Amazon. The ... around 70% of the region, threatening biodiversity and indigenous ... a pair of researchers from the Institut de Cincia ... (UAB), and the Washington DC-based NGO Save America,s Forests, ...
... SAN FRANCISCO Feb. 18, 2010 ... announced a strategic alliance that will help emerging ... Rondaxe, a drug development consulting company in ... navigate through all phases of the drug development ...
... Autnoma de Barcelona (UAB) researcher Deodoro Oliveira, have sequenced ... the genus Nasonia . The research offers new ... is also of great importance for the control of ... bite and lay eggs on much larger insects, many ...
Cached Biology News:A second hydrocarbon boom threatens the Peruvian Amazon 2A second hydrocarbon boom threatens the Peruvian Amazon 3Rondaxe and TD2 form strategic drug development alliance 2Genome sequencing of 3 parasitoid wasp species 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: